Timothy McDaniel

Vice President Of Technology Development

Professional Overview
Timothy McDaniel is a seasoned technology executive with over 20 years of experience driving innovation and advancing scientific research. As the Vice President of Technology Development at Delfi Diagnostics, he oversees the company's technology roadmap, leading cross-functional teams to develop and commercialize cutting-edge diagnostic solutions. Additionally, he serves as a Director on the Scientific Advisory Board at Deepcell, Inc., providing strategic guidance to the company's research and development initiatives.

Experience Summary

Current Role
As the Vice President of Technology Development at Delfi Diagnostics, Timothy is responsible for spearheading the company's technology strategy and development efforts. He leads a team of scientists and engineers in designing and implementing novel diagnostic platforms, with a focus on improving patient outcomes through earlier disease detection and monitoring. Under his leadership, Delfi Diagnostics has made significant strides in advancing its liquid biopsy technology, positioning the company as a leader in the field of precision oncology.

Career Progression
Prior to his current role, Timothy held various positions of increasing responsibility within the biotechnology and diagnostic industries. He served as a Senior Vice President, Emerging Opportunities at TGen - an Affiliate of City of Hope, where he identified and evaluated strategic opportunities to expand the organization's research and development capabilities. Earlier in his career, Timothy spent over a decade at Illumina, rising from a Scientist 1 to the Director of Research & Development, Oncology, contributing to the company's growth and technological advancements.

Academic Background
Timothy holds a PhD in Molecular Biology from the University of Maryland, Baltimore, where his research focused on the development of novel molecular diagnostic techniques. His academic achievements include several peer-reviewed publications and presentations at industry conferences, further solidifying his expertise in the field of molecular diagnostics.

Areas of Expertise

• Liquid biopsy and next-generation sequencing technologies

• Diagnostic platform development and commercialization

• Oncology research and biomarker discovery

• Cross-functional team leadership and collaboration

• Strategic planning and business development

Professional Impact
During his tenure at Illumina, Timothy spearheaded the development of several groundbreaking diagnostic assays, including the company's first FDA-approved liquid biopsy test for cancer monitoring. His work has been instrumental in advancing the field of precision medicine and improving patient outcomes through earlier disease detection and personalized treatment approaches.

Conclusion
Timothy McDaniel's extensive experience and proven track record of driving innovation in the biotechnology and diagnostic industries make him a valuable asset to Delfi Diagnostics and Deepcell, Inc. As a strategic leader and technical visionary, he is well-positioned to continue shaping the future of diagnostic technologies and positively impacting patient care.